- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
NX1
ASX
Week ended 07 Aug 2026
Weekly Investor Report
Nexalis Therapeutics Limited · Healthcare · Biotechnology
Latest close
0.01 AUD
0.0%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -44.6% below the Trend Line and sits at 3.3% of its 52-week range. The latest completed week returned 0.0%, after a 10.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100.
Setup score
15
out of 100
Latest Close
0.01 AUD
7 Aug 2026
1W Return
0.0%
latest completed week
4W Return
10.0%
short-term follow-through
12W Return
-50.0%
quarterly tape
Trend Breadth
9.6%
5 of 52 weeks active
Volume Ratio
-
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
Price follow-through
0.0%
Latest completed week; four-week move 10.0%.
Indicator stack
5/26
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 38.15%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
50/100
8 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -44.6% below the Trend Line and sits at 3.3% of its 52-week range. The latest completed week returned 0.0%, after a 10.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is - the 13-week average. Participation data is incomplete.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0712-week average 0.14
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure4/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.07Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 10.0% over four weeks, -50.0% over 12 weeks, and -72.5% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year5
Trend breadth9.6%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-1.19Latest activity-pressure read.
Pressure change-31.9%Four-week change in activity pressure.
Leadership-56.77Latest relative-leadership reading.
RS change9.1%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Dec 2025
Field coverage 42%
Model confidence 34%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength34/100Blend of value, momentum, and quality. Underlying universe rank 67; rank 1 is best.
Value39/100Relative valuation strength. Underlying universe rank 62; rank 1 is best.
Quality37/100Profitability and accounting quality. Underlying universe rank 64; rank 1 is best.
Momentum38/100Medium-term price momentum. Underlying universe rank 63; rank 1 is best.
Growth39/100Revenue and earnings growth. Underlying universe rank 62; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -28.8% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- - Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- - Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 1/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -17.2% Net share repurchases relative to market value.
- Shareholder yield
- -17.2% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.2x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 8 relevant articles.
0 positive · 8 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-72.5%Distance below the 52-week high.
13-week volatility21.4%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 269 weeks finished lower.
Best week+38.5%Week of 26 Jun.
Worst week-44.4%Week of 3 Jul.
Latest week+0.0%Week of 7 Aug.
Shape of recent returns
Strong gains12
Modest gains1
Flat weeks4
Modest losses0
Sharp losses9
Recent vol21.4%13-week weekly-return volatility.
Base vol15.5%52-week weekly-return volatility.
Up/down split21/22Count of positive and negative weeks in the 52-week window.
Average skew12.2% / -14.3%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorAU Healthcare
4-week rank- / 100
Group average-0.9%
Trend breadth25.0%
Trend25.0%active weekly trend signals
MD58.0%positive activity pressure
RS26.0%positive relative leadership
Four-week leaders
IndustryAU Biotechnology
4-week rank10 / 47
Group average-0.1%
Trend breadth29.8%
Trend29.8%active weekly trend signals
MD68.1%positive activity pressure
RS21.3%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape13/100
Trend, activity pressure, participation, and risk combine to a 13/100 tape read.
Indicator analysis17/100Latest 12-week confirmation: trend 0/12, activity pressure 4/12, relative leadership 0/12.
Activity pressure 0.07; No reversal markers Next-Week ExpectancyNegative 38.15%Next-week expectancy is negative with a 38.15% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors36/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 88 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 8 relevant articles.
Enterprise value to EBITDA forward of Nexalis Therapeutics Limited – ASX:NX1 Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 0.01 AUD | 0.0% | 0.02 AUD | 0.03 AUD | -1.19 | -56.77 | 0 | Off |
| 31 Jul 2026 | 0.01 AUD | 0.0% | 0.02 AUD | 0.03 AUD | -1.04 | -56.41 | 0 | Off |
| 24 Jul 2026 | 0.01 AUD | 0.0% | 0.02 AUD | 0.03 AUD | -1.07 | -56.47 | 10.2K | Off |
| 17 Jul 2026 | 0.01 AUD | 10.0% | 0.02 AUD | 0.03 AUD | -0.94 | -57.67 | 62.5K | Off |
| 10 Jul 2026 | 0.01 AUD | 0.0% | 0.02 AUD | 0.03 AUD | -0.90 | -62.43 | 3.5M | Off |
| 3 Jul 2026 | 0.01 AUD | -44.4% | 0.02 AUD | 0.03 AUD | -0.75 | -63.47 | 0 | Off |
| 26 Jun 2026 | 0.02 AUD | 38.5% | 0.02 AUD | 0.03 AUD | -0.61 | -35.06 | 0 | Off |
| 19 Jun 2026 | 0.01 AUD | -35.0% | 0.02 AUD | 0.03 AUD | -0.26 | -54.18 | 673.1K | Off |
| 12 Jun 2026 | 0.02 AUD | 17.6% | 0.02 AUD | 0.03 AUD | 0.29 | -31.03 | 66.8K | Off |
| 5 Jun 2026 | 0.02 AUD | -26.1% | 0.02 AUD | 0.03 AUD | 0.37 | -40.79 | 22.7K | Off |
| 29 May 2026 | 0.02 AUD | -8.0% | 0.02 AUD | 0.03 AUD | 0.63 | -22.09 | 175.9K | Off |
| 22 May 2026 | 0.03 AUD | 13.6% | 0.02 AUD | 0.03 AUD | 0.48 | -15.03 | 1.3M | Off |
| 15 May 2026 | 0.02 AUD | -8.3% | 0.02 AUD | 0.03 AUD | 0.12 | -25.15 | 470.4K | Off |
| 8 May 2026 | 0.02 AUD | 9.1% | 0.03 AUD | 0.03 AUD | 0.04 | -19.61 | 15.2K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.